Japan approved its 39-trillion-yen economic stimulus package on November 22. It does not explicitly state that the drug price revision…
HOME > TRENDS
TRENDS
- Japan Drug Makers Foresee 6% Sales Growth in FY2015: Jiho Tally
February 15, 2016
- 17,800 Hep C Patients Prescribed Sovaldi in 6 Months; Clinical Benefits Out of Consideration in New Re-Pricing Rule
January 27, 2016
- Global Pharmas Mull Excluding Japan from In-Licensing Deals on Annual Revision Fears, Softer Yen
January 26, 2016
- Takeda’s Exit from Diabetes Research a Symbolic Move under Weber Leadership
January 20, 2016
- Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
- “Huge Seller” Re-Pricing Targeting Hep C Drugs Will Dampen Innovative Market
December 9, 2015
- Peak Sales Forecast for New Drugs Listed in 2015 Exceeded 840 Billion Yen with Big Contribution from Hep C Treatments
December 7, 2015
- AG Shares Reach 50-60% in 1 Year; Confidence in Quality Encourages Dominance Even without Market Lead
November 30, 2015
- Full-Year Forecasts for Domestic Market Down vs Previous Year; Major Makers Struggling Even in Year without NHI Price Revision
November 11, 2015
- Shift to Specialty - 5: Eisai, Ajinomoto Jump on Specialty Bandwagon to Seek Efficiency in GI Biz
October 30, 2015
- Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
September 15, 2015
- Transformation of ARB Market Spurred by AGs, Power Map Changing Fast as Brand-Name Drugs Falter
September 4, 2015
- Japan Drug Makers See Rising Overseas Sales Ratios in April-June
August 11, 2015
- IFN-Free Drugs Upending Hepatitis C Market Landscape
July 17, 2015
- 3 Major Japan Makers Shed 1,300 Jobs amid Redundancy Programs
June 30, 2015
- “80% Generic” Era Would Further Accelerate Contraction of Market for Long-Listed Drugs
June 29, 2015
- Top-4 Japanese Drug Makers Report Widely Different Financial Results for FY2014
May 22, 2015
- Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?
April 24, 2015
- Global Drug Sales Rose 8.8% to US$936.5 Billion in 2014: IMS Health
April 3, 2015
- Development Tie-Ups with Immune Checkpoint Inhibitors Increase; to Maximize Value through Combination
March 27, 2015
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…